Opus Genetics, Inc. (IRD)

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst